Pipeline
JIN-NOVA Platform
Certificate
Notice
-
Convergence of
Science & Business -
Convergence of
Science & Business -
Convergence of
Science & Business -
Convergence of
Science & Business -
Convergence of
Science & Business
(Technology Transfer to Yuhan)Innovation in AI drug development, JIN-NOVA
J INTS BIO optimizes our bio-supercomputing infrastructure
and has established a cloud-based drug discovery environment
to consistently generate promising drug candidates.
Sustainability-Oriented Management Certifications and Systems at J INTS BIO
-
ISO 9001:2015Quality Management System Certified
Trusted Quality, Continuous Improvement
JINTS BIO has achieved ISO 9001 certification, ensuring systematic quality management and ongoing improvement to enhance customer satisfaction.
-
ISO 37001:2016Anti-Bribery Management System Certified
Ethics and Transparency, Global-Standard Integrity
JINTS BIO has obtained ISO 37001 certification by establishing a robust anti-bribery framework and operating with ethical and transparent governance.
-
ISO 37301:2021Compliance Management System Certified
Sustainable Management Based on Law and Ethics
JINTS BIO has received ISO 37301 certification, demonstrating our commitment to legal compliance and responsible, sustainable business practices.
Notice&News
Learn more
Press Releases
-
NoticeJ INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy
- Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST Professor Joung Ho Kim join a pioneering collaboration in pre 2024-12-15 -
Notice
J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- J INTS BIO provided an update of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGF 2024-06-10 -
Notice
J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study
SEOUL, South Korea, April 11, 2024 /PRNewswire/ -- J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation 2024-04-12 -
Notice
J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)
SEOUL, South Korea, Feb. 26, 2024 /PRNewswire/ -- J INTS BIO announced on the 26th of month that the Phase 1/2 clinical study of its Novel Oral 4th Ge 2024-02-26 -
Notice
J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023
'JIN-A02', a 4th generation EGFR-TKI, is a substance that selectively binds to C797S, a mutation that leads to resistance to 3rd generation EGFR-TKIs 2024-01-01 -
Notice
J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI
JIN-A02, a 4th generation EGFR TKI, selectively and reversibly binds to EGFR mutations, in particular C797S mutation that led to resistance to Osimert 2024-01-01 -
Notice
Yuhan Corporation Partners with J INTS BIO for 'HER2 Target TKI'
Yuhan Corporation announced on May 30 that it has signed a technology licensing agreement with J INTS BIO for the tyrosine kinase inhibitor (TKI) “JIN 2024-01-01 -
Notice
J INTS BIO, AACR 2023 - Presentation of preclinical study results of 'JIN-A04', an oral target therapy for HER2 exon insertion mutation NSCLC
SEOUL, South Korea, April 25, 2023 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered TKI 'JIN-A04' target 2023-12-09 -
Notice
J INTS BIO, Oral TKI 'JIN-A04', poster presentation of HER2 exon20 insertion mutation in NSCLC
SEOUL, South Korea, Feb. 6, 2023 /PRNewswire/ -- J INTS BIO announced that the preclinical results of "JIN-A04," a novel oral tyrosine kinase inhibito 2023-02-07 -
Notice
J INTS BIO, M.D Anderson Cancer Center joint development - oral HSP90 inhibitor 'JIN-001', presentation of preclinical assessment at 2022 SNO Annual Meeting
SEOUL, South Korea, Nov. 23, 2022 /PRNewswire/ -- J INTS BIO announced that the preclinical assessment of JIN-001 or MPT0B640, a novel, orally adminis 2022-11-23
Address.#311~313, 49 Achasan-ro 17-gil, Seongdong-gu, Seoul, Korea
TEL.+82-2-6008-0097 FAX.+82-70-4647-0090 E-mail.info@jintsbio.com
COPYRIGHT ⓒ J INTS BIO CO.,LTD. ALL RIGHTS RESERVED